Canada Life’s Corbus Pharmaceuticals CRBP Stock Holding History

Canada Life’s Portfolio CRBP Stock Details CRBP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-149	Closed	-$8K	–	2631
2020 Q3	$8K	Hold	149	–	–	﹤0.01%	2533
2020 Q2	$37K	Buy	+149	New	+$30.1K	﹤0.01%	2325

Other funds holding CRBP

EMG

ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $299B AUM 28.69% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Canada Life's CRBP Position: Q4 2020 in Review

Canada Life sold out of Corbus Pharmaceuticals (CRBP) in Q4 2020, closing a stake of 149 shares — an estimated $8K sold.

Canada Life first reported a position in CRBP in Q2 2020 and held it in 2 quarters. The position peaked at $37K in Q2 2020. 107 funds tracked by Wall St. Rank hold CRBP as of Q4 2020.

Canada Life reported no remaining Corbus Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
Canada Life sold 149 Corbus Pharmaceuticals shares in Q4 2020, an estimated $8K.
Canada Life first reported a position in Corbus Pharmaceuticals in Q2 2020 and held it in 2 quarters.
Canada Life's Corbus Pharmaceuticals position peaked at $37K in Q2 2020.
107 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q4 2020.

Based on Canada Life's 13F filing for Q4 2020, filed 16 Feb 2021.